Amicus Therapeutics, Inc. (NASDAQ:FOLD) had its target price boosted by equities researchers at Chardan Capital from $12.50 to $17.50 in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 39.11% from the stock’s previous close.
Other research analysts have also recently issued research reports about the company. Robert W. Baird reissued an “outperform” rating and issued a $12.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 12th. BidaskClub upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Amicus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $14.58.
Shares of Amicus Therapeutics (FOLD) opened at 12.58 on Thursday. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.05. The firm’s market cap is $1.80 billion. The company’s 50 day moving average price is $12.10 and its 200 day moving average price is $8.42. Amicus Therapeutics also was the target of some unusual options trading on Monday. Stock traders bought 11,013 call options on the company. This is an increase of approximately 666% compared to the average volume of 1,438 call options.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 66.85% and a negative net margin of 672.48%. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. Equities research analysts forecast that Amicus Therapeutics will post ($1.41) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) PT Raised to $17.50” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/10/amicus-therapeutics-inc-fold-pt-raised-to-17-50.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the business’s stock in a transaction on Thursday, July 13th. The stock was acquired at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 29,914 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the sale, the insider now owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Amicus Therapeutics by 4.2% in the first quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock worth $61,944,000 after buying an additional 353,949 shares in the last quarter. Palo Alto Investors LLC raised its stake in Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock worth $56,206,000 after buying an additional 1,472,958 shares in the last quarter. Janus Capital Management LLC raised its stake in Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock worth $50,883,000 after buying an additional 244,906 shares in the last quarter. Morgan Stanley raised its stake in Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after buying an additional 3,055,039 shares in the last quarter. Finally, State Street Corp raised its stake in Amicus Therapeutics by 0.9% in the first quarter. State Street Corp now owns 5,766,929 shares of the biopharmaceutical company’s stock worth $41,118,000 after buying an additional 50,982 shares in the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.